Showing results (91-100 of 135) with videos related to
Sort By:
Pageof 14
Nature Communications|September 7, 2023
The master energy homeostasis regulator PGC-1α exhibits an mRNA nuclear export functionSimeon R Mihaylov, Lydia M Castelli, Ya-Hui Lin, et al.Journal of Neurology, Neurosurgery, and Psychiatry|August 25, 2022
Exploring the phenotype of Italian patients with ALS with intermediate ATXN2 polyQ repeatsAdriano Chio, Cristina Moglia, Antonio Canosa, et al.Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|July 10, 2020
TRICALS: creating a highway toward a cureRuben P A van Eijk, Tessa Kliest, Christopher J McDermott, et al.Cell Reports|June 7, 2018
The NAD+ Precursor Nicotinamide Riboside Rescues Mitochondrial Defects and Neuronal Loss in iPSC and Fly Models of Parkinson's DiseaseDavid C Schöndorf, Dina Ivanyuk, Pascale Baden, et al.Brain : a Journal of Neurology|October 25, 2019
C9orf72 expansion within astrocytes reduces metabolic flexibility in amyotrophic lateral sclerosisScott P Allen, Benjamin Hall, Ryan Woof, et al.Neurology. Genetics|October 31, 2022
Clinical and Metabolic Signature of UNC13A rs12608932 Variant in Amyotrophic Lateral SclerosisAndrea Calvo, Antonio Canosa, Cristina Moglia, et al.Movement Disorders : Official Journal of the Movement Disorder Society|October 20, 2020
Plasma Neurofilament Light as a Biomarker of Neurological Involvement in Wilson's DiseaseSamuel Shribman, Carolin Heller, Maggie Burrows, et al.Movement Disorders : Official Journal of the Movement Disorder Society|May 29, 2023
A Double-Blind, Randomized, Placebo-Controlled Trial of Ursodeoxycholic Acid (UDCA) in Parkinson's DiseaseThomas Payne, Matthew Appleby, Ellen Buckley, et al.The Lancet. Neurology|February 1, 2017
Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trialVincent Meininger, Angela Genge, Leonard H van den Berg, et al.Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|September 30, 2021
Correlations between measures of ALS respiratory function: is there an alternative to FVC?Deirdre Murray, James Rooney, Amar Al-Chalabi, et al.Pageof 14